New oncology initiative and Health Canada study on biosimilar drugs
Newsletters
05 June 2019
The pan-Canadian Pharmaceutical Alliance and Cancer Care Ontario have partnered to create a pan-Canadian Oncology Biosimilars Initiative, which aims to ensure appropriate implementation and cost-effective use of therapeutic oncology biosimilars across Canada. In November 2018 the initiative held a pan-Canadian Oncology Biosimilars Summit. The initiative has released a summit proceedings report and an initiative action plan.
Separately, Health Canada announced that it is collaborating with the Drug Safety and Effectiveness Network on a project to study patients with inflammatory rheumatic diseases and inflammatory bowel disease who are taking biologic drugs.(1) The study aims to compare the safety and effectiveness of biosimilar drugs to the reference biologic drug.
For further information on this topic please contact Urszula Wojtyra at Smart & Biggar/Fetherstonhaugh by telephone (+1 416 593 5514) or email (uawojtyra@smart-biggar.ca). The Smart & Biggar/Fetherstonhaugh website can be accessed at www.smart-biggar.ca.
Endnotes
(1) The protocol for the study is available here.
The materials contained on this website are for general information purposes only and are subject to the disclaimer.
ILO is a premium online legal update service for major companies and law firms worldwide. In-house corporate counsel and other users of legal services, as well as law firm partners, qualify for a free subscription.
Author
